ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of ADMA Biologics Inc (NASDAQ:ADMA) have been given an average rating of “Hold” by the five analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $19.00.

ADMA has been the topic of a number of analyst reports. Mizuho lowered their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Canaccord Genuity Group lowered their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Zacks Research lowered ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $8.06 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of 11.85 and a beta of 0.73. The business’s 50-day simple moving average is $9.24 and its 200-day simple moving average is $14.37. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $22.37.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting analysts’ consensus estimates of $0.19. The business had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The firm’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.11 EPS. As a group, equities research analysts expect that ADMA Biologics will post 0.84 earnings per share for the current fiscal year.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman bought 12,500 shares of the stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the acquisition, the director directly owned 513,884 shares of the company’s stock, valued at $4,116,210.84. This represents a 2.49% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 3.90% of the stock is owned by company insiders.

Institutional Trading of ADMA Biologics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp grew its holdings in ADMA Biologics by 0.3% in the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after buying an additional 35,614 shares during the last quarter. Sachem Head Capital Management LP grew its holdings in ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after buying an additional 2,415,000 shares during the last quarter. Westfield Capital Management Co. LP grew its holdings in ADMA Biologics by 36.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after buying an additional 1,886,105 shares during the last quarter. Capital Research Global Investors grew its holdings in ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after buying an additional 3,383,559 shares during the last quarter. Finally, Nuveen LLC grew its holdings in ADMA Biologics by 3.5% in the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock valued at $108,097,000 after buying an additional 202,245 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.